Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential
Neurodegenerative diseases are among the most serious health problems affecting millions of people worldwide. Such diseases are characterized by a progressive degeneration and / or death of neurons in the central nervous system. Currently, there are no therapeutic approaches to cure or even halt the progression of neurodegenerative diseases. During the last two decades, much attention has been paid to the neuroprotective and anti-neurodegenerative activities of compounds isolated from natural products with high efficacy and low toxicity. Accumulating evidence indicates that berberine, an isoquinoline alkaloid isolated from traditional Chinese medicinal herbs, may act as a promising anti-neurodegenerative agent by inhibiting the activity of the most important pathogenic enzymes, ameliorating intracellular oxidative stress, attenuating neuroinflammation, triggering autophagy and protecting neurons against apoptotic cell death. This review attempts to summarize the current state of knowledge regarding the therapeutic potential of berberine against neurodegenerative diseases, with a focus on the molecular mechanisms that underlie its effects on Alzheimer’s, Parkinson’s and Huntington’s diseases.
Top-30
Journals
|
1
2
3
4
|
|
|
Frontiers in Pharmacology
4 publications, 6.35%
|
|
|
International Journal of Molecular Sciences
2 publications, 3.17%
|
|
|
Molecules
2 publications, 3.17%
|
|
|
Heliyon
2 publications, 3.17%
|
|
|
Food Science and Nutrition
2 publications, 3.17%
|
|
|
BioFactors
2 publications, 3.17%
|
|
|
International Journal of Biological Macromolecules
2 publications, 3.17%
|
|
|
Journal of Alzheimer's Disease
1 publication, 1.59%
|
|
|
Molecular Biotechnology
1 publication, 1.59%
|
|
|
Journal of Neuroinflammation
1 publication, 1.59%
|
|
|
NeuroReport
1 publication, 1.59%
|
|
|
Biomolecules
1 publication, 1.59%
|
|
|
Frontiers in Genetics
1 publication, 1.59%
|
|
|
Frontiers in Oncology
1 publication, 1.59%
|
|
|
Frontiers in Aging Neuroscience
1 publication, 1.59%
|
|
|
Biocell
1 publication, 1.59%
|
|
|
Plants
1 publication, 1.59%
|
|
|
Natural Products and Bioprospecting
1 publication, 1.59%
|
|
|
Journal of Functional Foods
1 publication, 1.59%
|
|
|
European Journal of Pharmacology
1 publication, 1.59%
|
|
|
Journal of Ethnopharmacology
1 publication, 1.59%
|
|
|
Life Sciences
1 publication, 1.59%
|
|
|
Journal of Drug Delivery Science and Technology
1 publication, 1.59%
|
|
|
Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology
1 publication, 1.59%
|
|
|
CNS and Neurological Disorders - Drug Targets
1 publication, 1.59%
|
|
|
Food and Function
1 publication, 1.59%
|
|
|
Evidence-based Complementary and Alternative Medicine
1 publication, 1.59%
|
|
|
Current Molecular Pharmacology
1 publication, 1.59%
|
|
|
Phytomedicine
1 publication, 1.59%
|
|
|
1
2
3
4
|
Publishers
|
2
4
6
8
10
12
14
16
18
|
|
|
Elsevier
17 publications, 26.98%
|
|
|
Springer Nature
8 publications, 12.7%
|
|
|
Frontiers Media S.A.
8 publications, 12.7%
|
|
|
Wiley
8 publications, 12.7%
|
|
|
MDPI
7 publications, 11.11%
|
|
|
Bentham Science Publishers Ltd.
4 publications, 6.35%
|
|
|
IOS Press
1 publication, 1.59%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 1.59%
|
|
|
Tech Science Press
1 publication, 1.59%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 1.59%
|
|
|
IntechOpen
1 publication, 1.59%
|
|
|
Hindawi Limited
1 publication, 1.59%
|
|
|
British Editorial Society of Bone and Joint Surgery
1 publication, 1.59%
|
|
|
AME Publishing Company
1 publication, 1.59%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 1.59%
|
|
|
SAGE
1 publication, 1.59%
|
|
|
2
4
6
8
10
12
14
16
18
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.